10X Genomics reported a GAAP loss of $42.413 million for the 3 months of 2022, up 3.7 times from $11.551 million in the prior year. Revenue increased 8.2% to $114.496 million from $105.821 million a year earlier.

10X Genomics' GAAP loss for 2021 was $58.223 million, down 9.4 times from $542.731 million in the previous year. Revenue increased 64.1% to $490.49 million from $298.845 million a year earlier.

10X Genomics' GAAP loss for 9M 2021 was $39.774 million, down 3.2 times from $127.158 million in the prior year. Revenue increased 85.9% to $346.96 million from $186.627 million a year earlier.

10x Genomics opened its first manufacturing facility outside the U.S. in Singapore. The center is designed to produce a core portfolio of consumables for single-cell and spatial analysis. The facility also serves as a commercial hub in the APAC, strengthening sales, marketing and customer support in the region.